Leap Investments’s Sage Therapeutics SAGE Stock Holding History

Leap Investments’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-6,000	Closed	-$842K	–	557
2019 Q3	$842K	Buy	+6,000	New	+$1M	0.42%	77

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Leap Investments's SAGE Position: Q4 2019 in Review

Leap Investments sold out of Sage Therapeutics (SAGE) in Q4 2019, closing a stake of 6,000 shares — an estimated $842K sold.

Leap Investments first reported a position in SAGE in Q3 2019 and held it in 1 quarter. The position peaked at $842K in Q3 2019. 266 funds tracked by Wall St. Rank hold SAGE as of Q4 2019.

Leap Investments reported no remaining Sage Therapeutics position as of Q4 2019 after selling out during the quarter.
Leap Investments sold 6,000 Sage Therapeutics shares in Q4 2019, an estimated $842K.
Leap Investments first reported a position in Sage Therapeutics in Q3 2019 and held it in 1 quarter.
Leap Investments's Sage Therapeutics position peaked at $842K in Q3 2019.
266 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2019.

Based on Leap Investments's 13F filing for Q4 2019, filed 14 Feb 2020.